Related Experiment Video
Updated: Jul 11, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Concurrent chemoradiation therapy for advanced cervical cancer]
Shigeki Takeshita1, Hiroshi Ichida, Akinori Kayama
1Department of Obstetrics and Gynecology, Teikyo University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 19, 2007
Summary
Concurrent chemoradiation therapy (CCR) showed a 75% response rate in advanced cervical cancer patients. However, long-term survival benefits require further investigation.
Area of Science:
- Oncology
- Gynecologic Oncology
- Radiation Oncology
Background:
- Cervical cancer remains a significant global health concern.
- Concurrent chemoradiation therapy (CCR) is a standard treatment approach.
- Evaluating CCR's efficacy and safety in advanced stages is crucial.
Purpose of the Study:
- To assess the clinical application and outcomes of CCR in patients with advanced cervical cancer (FIGO stages IIa-IIIb).
Main Methods:
- Analysis of 14 advanced cervical cancer patients treated with CCR.
- Radiation therapy included external beam radiotherapy (50 Gy) and brachytherapy (20 Gy).
- Cisplatin chemotherapy (70 mg/m(2) IV every 3 weeks) was administered concurrently.
Main Results:
- Overall response rate was 75% (58.3% complete response, 16.7% partial response).
- 83.3% of patients achieved viable cell negativity post-CCR.
- Grade 3 adverse effects included leukopenia, diarrhea, and anemia. Two patients discontinued CCR due to side effects.
Conclusions:
- CCR demonstrates significant antitumor effects in advanced cervical cancer.
- While effective in the short term, CCR did not show a statistical survival difference compared to radiation alone.
- Patients with suspected paraaortic lymph node metastasis had a poor prognosis, necessitating further research into long-term survival benefits.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...